NT5E and glioblastoma: Goswami et al. identified CD73 as a specific immunotherapy target which enhances the antitumor immune response to immune checkpoint therapy in GBM using scRNA-seq (69), and Cheng et al. identified 31 genes that could be biomarkers for GBM tumor cells based on single cell sequencing (70).